Announcements

13APR

Removal of Component(s) – FPRX

Effective at the market close on Thursdsay, April 15, 2021, FPRX will be removed from the LifeSci Biotechnology Clinical Trials Index and its values will be redistributed to the remaining index components based on their weights. On March 4, 2021, Five Prime Therapeutics agreed to be acquired by Amgen for $38.00 per share in cash.

11MAR

Removal of Component(s) – VIE

Effective at the market close on Friday March 12, VIE will be removed from the LifeSci Biotechnology Products Index and its values will be redistributed to the remaining index components based on their weights. On February 1, 2021, Viela Bio agreed to be acquired by Horizon Therapeutics plc for $53.00 per share in cash.

21JAN

Removal of Component(s) – EIDX, PRVL

Effective at the market close on Thursday January 21, EIDX and PRVL will be removed from the LifeSci Biotechnology Clinical Trials Index and their values will be redistributed to the remaining index components based on their weights. On October 5, 2020, Eidos agreed to be acquired by BridgeBio for a combination of cash and stock. On December 15, 2020, Prevail agreed to be acquired by Eli Lilly for $26.50/share in cash.

14DEC

Index Semi-Annual Reconstitution (Final) - December 2020

LifeSci Biotechnology Products Index LifeSci Biotechnology Clinical Trials Index The LifeSci Biotechnology Products Index and the LifeSci Biotechnology Clinical Trials Index will be reconstituted as of the market open on Wednesday, December 16, 2020. All positions will be equally weighted, with weights determined as of the closing prices on Monday, December 14, 2020. The final changes are summarized below. LifeSci Biotechnology Clinical Trials Index Additions (45 stocks): ADCT, AFMD, ALBO, ALVR, ALXO, AMTI, ANNX, ARCT, CDXS, CLDX, COGT, CRDF, CVAC, ETNB, FMTX, FPRX, GMDA, HGEN, IMAB, IMTX, IMVT, INBX, INO, ISEE, ITOS, KROS, LEGN, MCRB, MORF, NK, NKTX, ORIC, PGEN, PLRX, REPL, RLAY, RNA, RPTX,

09DEC

Semi-Annual Reconstitution (Preliminary) - December 2020

The LifeSci Biotechnology Products Index and the LifeSci Biotechnology Clinical Trials Index will be reconstituted as of the market open on Wednesday, December 16, 2020. All positions will be equally weighted, with weights determined as of the closing prices on Monday, December 14, 2020. The preliminary changes, subject to modification, are summarized below. LifeSci Biotechnology Clinical Trials Index Additions (45 stocks): ADCT, AFMD, ALBO, ALVR, ALXO, AMTI, ANNX, ARCT, CDXS, CLDX, COGT, CRDF, CVAC, ETNB, FMTX, FPRX, GMDA, HGEN, IMAB, IMTX, IMVT, INBX, INO, ISEE, ITOS, KROS, LEGN, MCRB, MORF, NK, NKTX, ORIC, PGEN, PLRX, REPL, RLAY, RNA, RPTX, SRRK, STOK, STRO, TCRR, UROV,

11NOV

Removal of Component(s) – MYOK

Effective at the market close on Friday November 13, 2020, MYOK will be removed from the LifeSci Biotechnology Clinical Trials Index and its value will be redistributed to the remaining index components based on their weights. On October 5, 2020, MyoKardia, Inc. agreed to be acquired by Bristol Myers Squibb for $225.00 per share in cash.

21OCT

Removal of Component(s) – IMMU

Effective at the market close on Thursday October 22, 2020, IMMU will be removed from the LifeSci Biotechnology Products Index and its value will be redistributed to the remaining index components based on their weights. On September 13, 2020, Immunomedics agreed to be acquired by Gilead Sciences for $88.00 per share in cash.

29SEP

Removal of Component(s) – AIMT, AKCA, MNTA

Effective at the market close on Wednesday September 30, 2020, AIMT, AKCA and MNTA will be removed from the LifeSci Biotechnology Products Index and their values will be redistributed to the remaining index components based on their weights. On August 19, 2020, Momenta Pharmaceuticals agreed to be acquired by Johnson & Johnson for $52.50 per share in cash. On August 31, 2020, Akcea Therapeutics agreed to be acquired by Ionis for $18.15 per share in cash. On August 31, 2020, Aimmune Therapeutics agreed to be acquired by Nestle Health Science for $34.50 per share in cash.

24SEP

Removal of Component(s) – PRNB

Effective at the market close on Friday September 25, 2020, PRNB will be removed from the LifeSci Biotechnology Clinical Trials Index and its value will be redistributed to the remaining index components based on their weights. On August 17, 2020, Principia Biopharma agreed to be acquired by Sanofi for $100.00 per share in cash.

11JUN

Index Semi-Annual Reconstitution (Final) - June 2020

The LifeSci Biotechnology Products Index and the LifeSci Biotechnology Clinical Trials Index will be reconstituted as of the market open on Tuesday, June 16, 2020. All positions will be equally weighted, with weights determined as of the closing prices on Friday, June 12, 2020. The final changes are summarized below. LifeSci Biotechnology Clinical Trials Index Additions (45 stocks): ADAP, APLT, APRE, ARQT, BCEL, BDTX, BNTX, BTAI, CALA, CGEN, CRNX, CUE, DVAX, EDIT, FREQ, HARP, IGMS, KNSA, KZR, MEIP, MIRM, MRNS, MRSN, MTEM, NGM, NTLA, NVAX, OVID, OYST, PHAT, PRTA, PRVL, PTGX, RAPT, RCUS, RLMD, RUBY, RVMD, SELB, SNDX, SYRS, VIE, VIR, VSTM, XENE Deletions

09JUN

Index Semi-Annual Reconstitution (Preliminary) - June 2020

Index Semi-Annual Reconstitution (Preliminary) The LifeSci Biotechnology Products Index and the LifeSci Biotechnology Clinical Trials Index will be reconstituted as of the market open on Tuesday, June 16, 2020. All positions will be equally weighted, with weights determined as of the closing prices on Friday, June 12, 2020. The preliminary changes, subject to modification, are summarized below. LifeSci Biotechnology Clinical Trials Index Additions (45 stocks): ADAP, APLT, APRE, ARQT, BCEL, BDTX, BNTX, BTAI, CALA, CGEN, CRNX, CUE, DVAX, EDIT, FREQ, HARP, IGMS, KNSA, KZR, MEIP, MIRM, MRNS, MRSN, MTEM, NGM, NTLA, NVAX, OVID, OYST, PHAT, PRTA, PRVL, PTGX, RAPT, RCUS, RLMD, RUBY, RVMD, SELB,

03APR

Removal of Component(s) – FTSV

4/3/2020 Effective at the market close on Monday, April 6, 2020, FTSV will be removed from the LifeSci Biotechnology Clinical Trials Index and its value will be redistributed to the remaining index components based on their weights. On March 2, 2020, Forty Seven agreed to be acquired by Gilead for $95.50 per share in cash.

30MAR

Removal of Component(s) – RARX

3/30/2020 Effective at the market close on Wednesday, April 1, 2020, RARX will be removed from the LifeSci Biotechnology Clinical Trials Index and its value will be redistributed to the remaining index components based on their weights. On October 10, 2019, RA Pharmaceuticals agreed to be acquired by UCB for $48 per share in cash.

27JAN

Removal of Component(s) – ACHN

1/27/2020 Effective at the market close on Tuesday, January 28, 2020, ACHN will be removed from the LifeSci Biotechnology Clinical Trials Index and its value will be redistributed to the remaining index components based on their weights. On January 27, 2020, FTC approval was granted for Alexion Pharmaceuticals’ acquisition of Achillion Pharmaceuticals for $6.30/share in cash plus a non-tradeable contingent value right.

12DEC

Index Semi-Annual Reconstitution (Final) - December 2019

Index Semi-Annual Reconstitution (Final) The LifeSci Biotechnology Products Index and the LifeSci Biotechnology Clinical Trials Index will be reconstituted as of the market open on Tuesday, December 17, 2019. All positions will be equally weighted, with weights determined as of the closing prices on Friday, December 13, 2019. The preliminary changes, subject to modification, are summarized below. LifeSci Biotechnology Clinical Trials Index Additions (22 stocks): AKRO, ARDX, BBIO, CNST, CRSP, CRTX, CVM, DTIL, FIXX, KDMN, KOD, KRTX, NXTC, ODT, PRVB, RIGL, SWTX, TBIO, TPTX, XBIT, YMAB, ZYME Deletions (20 stocks): ABEO, AIMT, AKCA, ARQL, BGNE, BOLD, CBAY, GBT, GRTS, INSM, KALV, KPTI, LJPC, MGTA, PHAS, PRQR,